Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player [Seeking Alpha]
Harpoon Therapeutics, Inc. (HARP)
Last harpoon therapeutics, inc. earnings: 3/12 04:05 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Ozgu Arslan/iStock via Getty ImagesThesisHarpoon Therapeutics (NASDAQ:HARPsell-off that has Harpoon Therapeutics now selling at a very cheap price. The company trades at about a 35% discount to its cash value. That cash value may well grow with another $200 million or more in the coming months, if AbbVie (ABBV) would exercise its option to further develop HPN328 or other drug candidates.HPN536 and HPN328 maintain activity even when tumors are expressing lower levels of antigens, and are independent of MHC expression. The latter is important as lack of MHC expression is a typical immune-evading characteristic of tumors. They furthermore allow for once-weekly dosing instead of continuous IV-infusion.With the T-cell engager field looked at as promising, and a recent competitor $1.3 billionbuyout by AstraZenecaInterim date for drug candidate HPN217 in multiple myeloma is slated for the coming months. Data for HPN328 will follow in the first half of 2023.The risk/reward ratio is currently
Show less
Read more
Impact Snapshot
Event Time:
HARP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HARP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HARP alerts
High impacting Harpoon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HARP
News
- Merck: A High-Conviction Investment For Long-Term Growth [Seeking Alpha]Seeking Alpha
- Harpoon Therapeutics, Inc. (NASDAQ: HARP) had its "neutral" rating re-affirmed by analysts at Citigroup Inc.. They now have a $23.00 price target on the stock, up previously from $13.00.MarketBeat
- INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, TARO, FFNWGlobeNewswire
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – HARP, FGH, BBAIAccesswire
- INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, JNPR, TGAN, TASTPR Newswire
HARP
Sec Filings
- 3/12/24 - Form EFFECT
- 3/12/24 - Form EFFECT
- 3/12/24 - Form EFFECT
- HARP's page on the SEC website